Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Shares Spike on Analyst Upgrade

NEW YORK (GenomeWeb News) – Shares in Cepheid have climbed more than 8 percent today following a morning upgrade of the company's stock by an analyst with William Blair & Co.

Analyst Brian Weinstein upgraded Cepheid shares to "outperform" from "market perform," noting expected revenues from new diagnostic products and increased hospital spending in 2010.

In afternoon trading on Nasdaq, Cepheid's shares had risen 8.3 percent to $15.58 from $14.38 at close of market on Friday.

Last week, Sunnyvale, Calif.-based Cepheid said that the US Food and Drug Administration had granted Emergency Use Authorization for its Xpert Flu A Panel test; as well as permission to market its Xpert vanA test for the antimicrobial resistance gene most commonly associated with vancomycin-resistant enterococci.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.